HLA-C and neoplasm: The non-MHC molecule-dependent recognition and killing of tumor cells and the high expression of NKG2D (an activating immune receptor expressed by NK and effector T cells), which are unique to γδ T cells, give them a broad spectrum of tumor cell killing.